SwedenLivingWorld world_2_fill WorldBusiness BusinessSports sports-soccer SportsEntertainmentEntertain

Medicine Stop a Hard Blow for Alzheimer's Patients

The disappointment is great since a new drug against Alzheimer's has been rejected by the EU's pharmaceutical authority. It is outrageous, says Liselotte Jansson at the Alzheimer's Foundation.

» Updated: October 08 2024

» Published: July 31 2024

Medicine Stop a Hard Blow for Alzheimer's Patients
Photo: Adam Ihse/TT

Expectations were sky-high ahead of the decision. But when the news came last week that the drug lecanemab would not be approved by the European Medicines Agency (EMA), it was a cold shower for patients and their relatives. This is according to Liselotte Jansson, Secretary-General of the Alzheimer's Foundation.

Many are very sad and disappointed. When this brake medicine is finally available, it's idiotic to stop it, especially since it has been approved by several other countries.

According to Liselotte Jansson, the rejection means that valuable time is being lost.

Patients with Alzheimer's do not have time on their side, it is their worst enemy.

A Tough Nut to Crack

In Alzheimer's, plaques form in the brain in the form of the protein beta-amyloid, which accumulates. Lecanemab has been long-awaited because it consists of antibodies that target the protein specifically, unlike today's medicines.

But the high expectations of the medicine have not been met, according to Alzheimer's researcher Hugo Lövheim at Umeå University.

Although lecanemab affects the underlying causes of Alzheimer's, the effect on patients' symptoms and disease progression has not been significant.

The motivation behind EMA's decision is that the benefit is not sufficient in relation to potential drawbacks and side effects, such as swelling and risk of bleeding in the brain.

The benefit is not that great, while the risks are not insignificant. So for us researchers, the decision is not entirely surprising, says Lövheim.

He continues:

Research has been going on for a long time, but Alzheimer's has proven to be a tough nut to crack. It has to do with the fact that we still don't have sufficient knowledge of the disease's various mechanisms.

The Final Word Not Said

He emphasizes that EMA's task is to protect patient safety.

It's clear that patients and their relatives have high hopes for new and better treatments. But amidst all the disappointment, one must remember how important it is for authorities to conduct their independent investigations.

The drug has previously been approved in, among others, the USA, Japan, and China. The Swedish company Bioarctic, which is behind the discovery that led to the drug, has announced that a review of the decision has been requested.

Hugo Lövheim does not rule out that there may be a change.

I don't think the final word has been said. If additional data that has not been presented before is added, it may change the picture.

Lecanemab has been approved in the USA, Japan, South Korea, China, Hong Kong, and Israel.

But the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) believes that the observed effect of slowing down cognitive decline does not outweigh the risk of serious side effects associated with the medicine.

Lecanemab, marketed under the brand name Leqembi, has been developed by the American pharmaceutical company Biogen and the Japanese company Eisai.

The drug is based on a discovery by Swedish researcher Lars Lannfeldt, professor at Uppsala University. The medicine has been developed, among others, by the Swedish company Bioarctic, which Lars Lannfeldt co-founded. Bioarctic receives a royalty on the global sales of lecanemab.

Sources: Dagens Medicin and others.

Among the dementia diseases, Alzheimer's disease is the most common. It is also quite common for Alzheimer's disease to occur in combination with vascular dementia (vascular dementia).

What they have in common is that they all involve problems with memory functions.

In Sweden, over 100,000 people have Alzheimer's disease.

The most important risk factors are high age and heredity.

In the disease, small clumps form on the nerve fibers, so-called amyloid plaques. They consist mainly of beta-amyloid, a type of protein. The plaques that form in the brain cells lead to nerve cells in the brain dying abnormally quickly.

Alzheimer's typically occurs after the age of 65. But it can also affect younger people, as early as in their 35s.

Sources: Alzheimer's Foundation, Demenscentrum, and others.

Tags

TTT
By TTThis article has been altered and translated by Sweden Herald

More news

This is why no weather warning was issued before the major crash
2 MIN READ

This is why no weather warning was issued before the major crash

Risbergska opens next week – in other premises
1 MIN READ

Risbergska opens next week – in other premises

Four cars collide in Stockholm – one to hospital
1 MIN READ

Four cars collide in Stockholm – one to hospital

The Liberals want more residence bans around schools
3 MIN READ

The Liberals want more residence bans around schools

Kristersson: High time for unity in Europe
2 MIN READ

Kristersson: High time for unity in Europe

School Chief Must Resign After Statements About Jihad
1 MIN READ

School Chief Must Resign After Statements About Jihad

Boy sentenced to prison for planning murder at a funeral
2 MIN READ

Boy sentenced to prison for planning murder at a funeral

Sweden needs a new security analysis
2 MIN READ

Sweden needs a new security analysis

Three acquitted of preparing for terrorist crimes
3 MIN READ

Three acquitted of preparing for terrorist crimes

Boy arrested for attempted murder with terrorist connections
1 MIN READ

Boy arrested for attempted murder with terrorist connections

Injured in Örebro Shooting No Longer in ICU
1 MIN READ

Injured in Örebro Shooting No Longer in ICU

Proposal: Deportees to be held in custody longer
3 MIN READ

Proposal: Deportees to be held in custody longer

Man arrested for threats against schools in Vansbro
1 MIN READ

Man arrested for threats against schools in Vansbro

Marco Polo: Security System Failures
3 MIN READ

Marco Polo: Security System Failures

After Örebro Tragedy: We Need to Adjust the Radar
5 MIN READ

After Örebro Tragedy: We Need to Adjust the Radar

The Prosecutor Demands Stricter Sentence for IS Woman
1 MIN READ

The Prosecutor Demands Stricter Sentence for IS Woman

The Police Investigate 100 Cases of Purchasing Sex After Operation
1 MIN READ

The Police Investigate 100 Cases of Purchasing Sex After Operation

The Foreign Minister Convenes an Emergency Ukraine Meeting
2 MIN READ

The Foreign Minister Convenes an Emergency Ukraine Meeting

Six Terror Suspects Have Had Assets Frozen
1 MIN READ

Six Terror Suspects Have Had Assets Frozen

Beware of Thieves during the Sports Break
2 MIN READ

Beware of Thieves during the Sports Break